PTAB designates seven IPR decisions as “informative”
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

PTAB designates seven IPR decisions as “informative”

ptab-web-icon.jpg

The Patent Trial and Appeal Board has designated seven of its decisions rendered in inter partes review (IPR) proceedings as “informative”

uspto.jpg

In each decision, the PTAB denied institution of an IPR under 35 USC § 325(d), which permits the Director to take into account whether, and reject the petition or request because, the same or substantially the same prior art or arguments previously were presented.

The seven decisions are:

Medtronic, Inc v Nuvasive Inc., Paper 8, No. IPR2014-00487 (September 11 2014)

Unified Patents Inc v PersonalWeb Techs., LLC, Paper 13, No. IPR2014-00702 (July 24 2014)

Prism Pharma Co v Choongwae Pharma Corp., Paper 14, No. IPR2014-00315 (July 8 2014)

Unilever, Inc v Procter & Gamble Co., Paper 17, No. IPR2014-00506 (July 7 2014)

Medtronic, Inc v Robert Bosch Healthcare Systems, Inc., Paper 17, No. IPR2014-00436 (June 19 2014)

Intelligent Bio-Systems Inc. v Illumina Cambridge Limited, Paper 19, No. IPR2013-00324 (November 21 2013)

ZTE Corp v ContentGuard Holdings, Inc., Paper 12, No. IPR2013-00454 (25 September 25 2013)

Decisions designated as "informative" can be viewed here.


more from across site and ros bottom lb

More from across our site

Partners and other senior leaders must step up if they want diverse talent at their firms to thrive
European and US counsel reveal why they are (or aren't) concerned about patent quality and explain how external counsel can help
Firms such as Bird & Bird and Taylor Wessing have reported rising profits and highlighted the role of high-profile IP disputes and hires
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Lawyers in the corporate and IP practices discuss where the firm can steal a march on competitors, its growth plans in London, and why deal lawyers are ‘concertmasters’
Kathleen Gaynor, DEI specialist at Phillips Ormonde Fitzpatrick, says deliberate actions can help law firms reach diversity goals
Scott McKeown, who moved to Wolf Greenfield one year ago, says the change has helped him tap into life sciences work and advise more patent owners
The winners of our Asia-Pacific Awards 2024 will be revealed during a ceremony in Malaysia on September 26
Zach Piccolomini of Wolf Greenfield explains how to maximise your IP portfolio’s value while keeping an eye on competitors
Witnesses at a Congressional hearing debated whether reforming the ITC is necessary and considered what any changes should look like
Gift this article